Biocon, Mylan launch biosimilar Ogivri for treatment of breast, stomach cancer in Australia

Ogivri is the first trastuzumab biosimilar approved and launched in Australia and available on the Pharmaceutical Benefits Scheme (PBS), Biocon and Mylan said in a joint statement.

New Delhi: Biotechnology major Biocon and Mylan NV on Thursday launched biosimilar Ogivri, which is used for the treatment of certain breast and stomach cancers in Australia. It is a biosimilar of Hoffmann-La Roche's Herceptin.

Ogivri is the first trastuzumab biosimilar approved and launched in Australia and available on the Pharmaceutical Benefits Scheme (PBS), the companies said in a joint statement.

Biocon Biologics Chief Executive Officer Christiane Hamacher said, "We are excited to enable access to Ogivri, in Australia, high-quality biosimilar trastuzumab, co-developed and manufactured by Biocon."

Read Also: NPPA notices worth Rs 101 crore sent to Biocon, Lupin, Dr Reddys, others for skipping regulatory nod-Minister

Commercialization of Ogivri by Mylan, in Australia, extends the global footprint of biosimilar trastuzumab, she added.

"Mylan's investment in biosimilars is an exciting evolution in how we can treat Australian patients. We are delighted that Ogivri enables Mylan, with our partner Biocon, to bring this treatment option to Australian patients with HER2-positive breast and gastric cancers," Mylan Australia Country Manager Sylvain Vigneault said.

Mylan and Biocon's trastuzumab biosimilar is currently approved in more than 65 countries around the world, including the US, the statement said.